ViNS Bioproducts

ViNS Bioproducts Limited, established in 1997, specializes in developing and producing life-saving antisera and immunoglobulins for treating critical conditions arising from venomous bites and infectious diseases. Based in Hyderabad, India, ViNS Bioproducts Limited focuses on the production of medical products designed to treat conditions caused by snake and scorpion bites, tetanus, diphtheria, and gangrene. The company was founded in 1997 and has established a strong operational base in Telangana. Its founder has a history of engaging in the bioproducts sector, although specific details on previous ventures are not available.

ViNS Bioproducts Ltd specializes in the development and production of life-saving antisera and immunoglobulins aimed at treating critical medical conditions resulting from snake and scorpion bites, tetanus, diphtheria, and gangrene. The company's primary product offerings include polyvalent snake venom antiserum, polyvalent scorpion venom antiserum, and equine rabies immunoglobulin, all designed for immediate use in emergency medical situations. These products are developed utilizing advanced manufacturing facilities located in Telangana, India, and are distributed to healthcare providers and emergency medical services across various markets, including South Asia, Africa, and parts of the Middle East. By providing effective treatment options for venomous bites and infectious diseases, ViNS Bioproducts addresses urgent healthcare needs, supporting patients and medical professionals in delivering timely interventions.

ViNS Bioproducts Ltd generates revenue primarily through direct sales of its specialized medical products to hospitals, clinics, and emergency medical service providers. The company engages in B2B transactions, establishing partnerships with healthcare institutions to ensure a steady supply of its flagship products, such as the ASVS Snake Venom Antiserum and VINRAB Equine Rabies Immunoglobulin. These products are sold under structured agreements that may include bulk purchasing options for hospitals, facilitating efficient distribution and inventory management. The sales model emphasizes both the reliability of product supply and adherence to regulatory standards in the healthcare sector, ensuring that clients receive high-quality medical solutions for urgent care scenarios.

ViNS Bioproducts Limited plans to expand its product line by developing new immunoglobulin treatments aimed at emerging infectious diseases, with initial launches expected within the next 18 months. The company is targeting expansion into markets in Southeast Asia and Africa by 2025. Recent funding will be allocated to enhance manufacturing capabilities and support research and development initiatives, ensuring the timely introduction of these new products.